Skip to main content
OpenTrials

Clinical trial condition

Refractory Myelodysplastic Syndrome

Explore clinical trials studying Refractory Myelodysplastic Syndrome. Study availability and eligibility vary by location and protocol.

22 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Refractory Myelodysplastic Syndrome trial results

Active, not recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

NCT03953898

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, +13 more
Locations
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Yale University New Haven, Connecticut, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
View Trial Details
Active, not recruiting

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT02890329

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +14 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Active, not recruiting

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

NCT05146739

Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Bone Marrow Diseases, Hematologic Diseases, +21 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Medical Center-Mission Bay San Francisco, California, United States
View all 19 locations
View Trial Details
Completed

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT03813147

Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Bone Marrow Diseases, Hematologic Diseases, +11 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Medical Center-Mission Bay San Francisco, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
View all 19 locations
View Trial Details

Related conditions